Analystreport

Takeda Pharmaceutical (NYSE:TAK) had its "hold (c+)" rating reaffirmed by analysts at Weiss Ratings.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)  (TAK)